Daiichi Sankyo to invest $1.9 billion in global cancer drug facilities - Nikkei
Daiichi Sankyo to invest $1.9 billion in global cancer drug facilities - Nikkei
BTC
ETH
USDT
XRP
USDC
SOL
TRX
FIGR_HELOC
DOGE
WBT
USDS
HYPE
LEO
ADA
BTC
ETH
USDT
XRP
USDC
SOL
TRX
FIGR_HELOC
DOGE
WBT
USDS
HYPE
LEO
ADA
BTC
ETH
USDT
XRP
USDC
SOL
TRX
FIGR_HELOC
DOGE
WBT
USDS
HYPE
LEO
ADA
BTC
ETH
USDT
XRP
USDC
SOL
TRX
FIGR_HELOC
DOGE
WBT
USDS
HYPE
LEO
ADA
Bitcoin bulls avoided a correction as US markets opened, but analysis warned that Strategy was responsible for much of the latest BTC price strength.
Most popular articles this week
Latest news from global stock markets, tech giants, and financial sectors
Browse ArticlesBitcoin, Ethereum, altcoins, DeFi, NFTs, and blockchain technology
Browse ArticlesGold, silver, oil, natural gas, and other precious commodities
Browse Articles
Daiichi Sankyo to invest $1.9 billion in global cancer drug facilities - Nikkei
Beyond the biggest chains, the past few years have largely been ones to forget for retailers, as shoppers have remained wary about spending amid a battle w...
Top hedge funds led by D.E.Shaw, Bridgewater and Balyasny deliver big gains in 2025
Equinor challenges US order to suspend Empire Wind project
Despite the sector's outperformance, there are still bargains to be found in the tech space.
S&P 500 swings between gains and losses but chip stocks shine
Tesla delivered 418,227 electric vehicles in the fourth quarter, down 15.6% from 495,570 in Q4 2024. TSLA shares angled higher early before falling in Frid...
Tesla's rough year took it to its second straight annual sales decline, and saw it lose its global EV sales leadership to China's BYD.
TRM Labs has said crypto has become a geopolitical tool across borders now as states test sanctions bypass, industrial mining, and hacking. It has linked D...
China controls around 70% of the silver that Big Tech, AI and solar power desperately need. Beijing is locking the gates.
SK Hynix undervalued as HBM pricing tightens into 2026, MS bumps target
Polyrizon stock rises on FDA submission for PL-16 viral blocker